In biotech’s Anteo Diagnostics (ADO) tumbled 11% on heavy sales volume to 16c (down from 28c last month), on the
flip side Admedus (AHZ) looks to have stabilised circa 13c and support is building again. The two companies seemed to
have a Ying/Yang relationship and investors/traders rotate from one to the other. We think Admedus will ultimately be the
winner as tangible sales build up from their Cardiocel product. OMF Report 16.04
thoughts on ado, page-20
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
